Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
The chronic spontaneous urticaria market is witnessing significant growth, driven by increasing disease awareness, improved diagnosis rates, and the rising prevalence of treatment-refractory patients. The introduction of emerging therapies such as Barzolvolimab (CDX-0159) (Celldex Therapeutics), Rilzabrutinib (Sanofi), Briquilimab (Jasper Therapeutics), EVO756 (Evommune), and others will further propel the market growth.
LAS VEGAS, June 24, 2026 /PRNewswire/ -- Recently published Chronic Spontaneous Urticaria Market Insights report includes a comprehensive understanding of current treatment practices, chronic spontaneous urticaria emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Chronic Spontaneous Urticaria Market Summary
Discover the chronic spontaneous urticaria treatments with best digital health tools @ http://delveinsight.com/report-store/chronic-spontaneous-urticaria-market
Key Factors Driving the Growth of the Chronic Spontaneous Urticaria Market
Ramandeep Singh, senior consultant of forecasting at DelveInsight, said that advancements in biologic therapies, such as omalizumab, have shown strong efficacy in antihistamine-refractory CSU, providing targeted and effective options for difficult-to-treat patients.
Chronic Spontaneous Urticaria Market Analysis
Chronic Spontaneous Urticaria Competitive Landscape
Some of the CSU drugs under development include Barzolvolimab (CDX-0159) (Celldex Therapeutics), Rilzabrutinib (Sanofi), Briquilimab (Jasper Therapeutics), EVO756 (Evommune), BLU-808 (Blueprint Medicines), ARS -1 (ARS Pharmaceuticals), bexobrutideg (NX-5948), bexobrutideg (NX-5948) (Nurix Therapeutics), INF904 (InflaRx), TAS5315 [Otsuka Holdings (Taiho Pharmaceutical)], and others.
Celldex Therapeutics' Barzolvolimab is a humanized monoclonal antibody designed to specifically inhibit KIT, a receptor tyrosine kinase essential for mast cell growth, activation, and migration into tissues. Given the central role of mast cells in the inflammatory processes underlying chronic spontaneous urticaria (CSU), targeting KIT represents a promising strategy for disease management.
Sanofi's Rilzabrutinib is an orally administered, reversible covalent inhibitor of Bruton's tyrosine kinase (BTK) being developed as a potential first- or best-in-class treatment for a range of immune-mediated disorders. By selectively targeting BTK, a key signaling molecule found in both B cells and mast cells that regulates immune responses, rilzabrutinib utilizes Sanofi's proprietary TAILORED COVALENCY technology to enhance target specificity while reducing unintended effects on other pathways.
Jasper Therapeutics' Briquilimab is an investigational monoclonal antibody currently in Phase Ib/IIa development that targets the stem cell factor (SCF)/CD117 (c-Kit) signaling axis, which is critical for mast cell maintenance. By preventing the interaction between SCF and CD117, briquilimab aims to deplete mast cells in affected tissues, potentially providing therapeutic benefit to CSU patients who do not achieve adequate symptom control with antihistamine therapy.
The anticipated launch of these emerging therapies are poised to transform the chronic spontaneous urticaria market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic spontaneous urticaria market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the most effective treatment options for chronic spontaneous urticaria @ Chronic Spontaneous Urticaria Treatment Guidelines 2026
Recent Developments in the Chronic Spontaneous Urticaria Market
What is Chronic Spontaneous Urticaria?
Chronic spontaneous urticaria (CSU) is a chronic inflammatory skin disorder characterized by the recurrent appearance of itchy wheals (hives), angioedema, or both, occurring spontaneously without an identifiable external trigger for six weeks or longer. The condition is driven by the activation of mast cells and basophils, which release histamine and other inflammatory mediators, leading to redness, swelling, and intense itching. CSU can significantly impair patients' quality of life by disrupting sleep, daily activities, work productivity, and emotional well-being. Although the exact cause remains unclear, autoimmune mechanisms are believed to play a key role in many patients. The disease affects individuals of all ages and often requires long-term management with antihistamines, biologics, or other targeted therapies to control symptoms and prevent recurrence.
Chronic Spontaneous Urticaria Epidemiology Segmentation
The chronic spontaneous urticaria epidemiology section provides insights into the historical and current chronic spontaneous urticaria patient pool and forecasted trends for the leading markets. Among the 7MM, the US accounted for nearly 19% of the total diagnosed prevalent cases of chronic urticaria, with around 920,000 cases in 2025.
The chronic spontaneous urticaria treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Chronic Spontaneous Urticaria Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Chronic Spontaneous Urticaria Epidemiology Segmentation
Total Diagnosed Prevalent Cases of Chronic Urticaria, Type-specific Cases of Chronic Urticaria, Gender-specific Cases of CSU, Age-specific Cases of CSU, and Severity-specific Cases of CSU
Chronic Spontaneous Urticaria Market Size in 2025
USD 2 Billion
Key Chronic Spontaneous Urticaria Companies
Celldex Therapeutics, Sanofi, Jasper Therapeutics, Evommune, Blueprint Medicines, ARS Pharmaceuticals, Nurix Therapeutics, InflaRx, Otsuka Holdings (Taiho Pharmaceutical), Regeneron Pharmaceuticals, Novartis, and others
Key Chronic Spontaneous Urticaria Therapies
Barzolvolimab (CDX-0159), Rilzabrutinib, Briquilimab, EVO756, BLU-808, ARS -1, bexobrutideg (NX-5948), INF904, TAS5315, DUPIXENT, RHAPSIDO, and others
Scope of the Chronic Spontaneous Urticaria Market Report
Download the report to understand the average treatment costs chronic spontaneous urticaria @ Chronic Spontaneous Urticaria Treatments Cost and Coverage
Table of Contents
1
Chronic Spontaneous Urticaria Market Key Insights
2
Chronic Spontaneous Urticaria Market Report Introduction
3
CSU Market Overview at a Glance
3.1
Market Share (%) Distribution of CSU by Therapies in the 7MM in 2025
3.2
Market Share (%) Distribution of CSU by Therapies in the 7MM in 2036
4
Executive Summary
5
Key Events
6
Disease Background and Overview
6.1
Introduction
6.2
Signs and symptoms
6.3
Classification
6.4
Causes
6.5
Pathophysiology
6.6
Clinical Manifestation
6.7
Diagnosis
6.8
Treatment and Management
7
Methodology
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: The 7MM
8.2.1
Diagnosed Prevalent Cases of Chronic Urticaria
8.2.2
Type-specific Cases of Chronic Urticaria
8.2.3
Gender-specific Cases of CSU
8.2.4
Age-specific Cases of CSU
8.2.5
Severity-specific Cases of CSU
8.3
Total Diagnosed Prevalent Cases of CSU in the 7MM
8.4
The US
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey
10
Marketed Chronic Spontaneous Urticaria Drugs
10.1
DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
10.1.1
Product Description
10.1.2
Regulatory Milestones
10.1.3
Other Developmental Activities
10.1.4
Clinical Trials Information
10.1.5
Safety and Efficacy
10.2
RHAPSIDO (remibrutinib): Novartis
List to be continued in the final report..
11
Emerging Chronic Spontaneous Urticaria Drugs
11.1
Key Cross Competition
11.2
Barzolvolimab (CDX-0159): Celldex Therapeutics
11.2.1
Drug Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Trials Information
11.2.4
Safety and Efficacy
11.2.5
Analysts' View
11.3
Rilzabrutinib: Sanofi
11.4
Briquilimab: Jasper Therapeutics
11.5
INF904: InflaRx
11.6
EVO756: Evommune
11.7
TAS5315: Otsuka Holdings (Taiho Pharmaceutical)
List to be continued in the final report..
12
CSU Market – 7MM Market Analysis
12.1
Key Findings
12.2
Chronic Spontaneous Urticaria Market Outlook
12.3
Attribute Analysis
12.4
Key Chronic Spontaneous Urticaria Market Forecast Assumptions
12.5
Total Market Size of CSU in the 7MM
12.6
Market Size of CSU by Therapies in the 7MM
12.7
The US Chronic Spontaneous Urticaria Market
12.7.1
Total Market Size of CSU in the US
12.7.2
Market Size of CSU by Therapies in the US
12.8
EU4 and the UK Chronic Spontaneous Urticaria Market
12.9
Japan Chronic Spontaneous Urticaria Market
13
Key Opinion Leaders' Views
14
Unmet Needs
15
SWOT Analysis
16
Chronic Spontaneous Urticaria Market Access and Reimbursement
16.1
The United States
16.2
EU4 and the UK
16.3
Japan
17
Acronyms and Abbreviations
18
Bibliography
19
Chronic Spontaneous Urticaria Market Report Methodology
Related Reports
BTK Inhibitors Market
BTK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key BTK inhibitors companies, including BeiGene, Nurix Therapeutics, Roche, Genentech, Sanofi, Principia Pharma, Novartis, ACEA Therapeutics, InnoCare Pharma, and others.
Chronic Spontaneous Urticaria Clinical Trial Analysis
Chronic Spontaneous Urticaria Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic spontaneous urticaria companies, including United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP., Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, and others.
Chronic Inducible Urticaria Market
Chronic Inducible Urticaria Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic inducible urticaria companies including Sanofi, Allakos Inc., Celldex Therapeutics, and others.
Chronic Inducible Urticaria Clinical Trial Analysis
Chronic Inducible Urticaria Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic inducible urticaria companies, including Celldex Therapeutics, Jasper Therapeutics, and others.
Urticaria Pipeline
Urticaria Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key urticaria companies, including Regeneron Pharmaceuticals, Taiho Pharmaceutical Co., Ltd, Allakos Inc, Yuhan Corporation, United BioPharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Kiniksa Pharmaceuticals, Ltd., Celldex Therapeutics, Longbio Pharma, Celltrion, Enanta Pharmaceuticals, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP